-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bezuclastinib in Systemic Mastocytosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bezuclastinib in Systemic Mastocytosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bezuclastinib in Systemic Mastocytosis Drug Details: Bezuclastinib (CGT-9486) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lemzoparlimab in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lemzoparlimab in Marginal Zone B-cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lemzoparlimab in Marginal Zone B-cell Lymphoma Drug Details: TJC-4...
-
Product Insights
Recurrent Glioblastoma Multiforme (GBM) – Drugs In Development, 2023
Global Markets Direct’s, ‘Recurrent Glioblastoma Multiforme (GBM) - Drugs In Development, 2023’, provides an overview of the Recurrent Glioblastoma Multiforme (GBM) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Recurrent Glioblastoma Multiforme (GBM), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PTZ-201 in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PTZ-201 in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PTZ-201 in Recurrent Glioblastoma Multiforme (GBM) Drug Details:PTZ-201 (ASP-8374) is under...
-
Product Insights
RFI – Taranto-Metaponto-Potenza-Battipaglia High-speed Railway line – Basilicate
Equip yourself with the essential tools needed to make informed and profitable decisions with our RFI - Taranto-Metaponto-Potenza-Battipaglia High-speed Railway line - Basilicate report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into the...
-
Product Insights
Non-Small Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non-Small Cell Lung Cancer Pipeline Drugs Market Report Overview Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC is a cancer (malignancy) that originates in the tissues of the lungs or the cells lining the airways. Symptoms of lung cancer usually occur in the later stages of the disease. The signs and symptoms include a persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody...
-
Product Insights
Colorectal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Colorectal Cancer Pipeline Drugs Market Overview Colorectal cancer starts in the colon or the rectum. It begins as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools, and weight loss with no known reasons. Risk factors for colorectal cancer include smoking, heavy alcohol use, inflammatory bowel disease (IBD), and family history. Treatment includes...
-
Product Insights
Prostate Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Prostate cancer usually occurs in older men. Its symptoms include problems while urinating, decreased force in the stream of urine, blood in the urine, pain in the lower back, hips, or thighs, bone pain, and erectile dysfunction. The Prostate Cancer pipeline market research report provides comprehensive information on the therapeutics under development for Prostate Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the...
-
Product Insights
Bladder Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Bladder cancer occurs in tissues of the urinary bladder whose symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body, and burning during urination. Risk factors for bladder cancer include smoking, exposure to substances such as rubber, certain dyes and textiles, paint, and hairdressing supplies, diet rich in fried meats and fat, old age, sex and color, and certain parasitic infections. The Bladder Cancer pipeline market research report provides comprehensive...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – PTZ-201
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry PTZ-201 Drug Details PTZ-201 (ASP-8374) is under development for the treatment of solid tumors...